(Total Views: 442)
Posted On: 02/27/2020 11:42:15 PM
Post# of 156923
Re: jacketsndisney #19639
Quote:
My management fails to fully capture scenario means that for whatever reason they fail to properly advance the potential of Leronlimab and have to sell at a "fire sale" price of 2-3 billion.
$2 billion is the low end for yearly sales for leronlimab in U.S. in combo alone. I can't foresee Cytodyn being sold for anything close to that low.
Right now it's simply a waiting game with Amarex and AGC to get their act together. On the cancer front things are progressing. Things are going forward in China and leronlimab will work to save the lives of those with COVID -19. Once revenue starts or we receive other financing more trials are ready to start.
(1)
(0)
